Pharmaceutical company Inotiv has notified the US Securities and Exchange Commission (SEC) that its business operations took a hit after hackers compromised and encrypted its internal systems.
The incident, the organization said in a Form 8-K filing, occurred on August 8, and prompted Inotiv to initiate containment and remediation processes.
“The company’s preliminary investigation determined that a threat actor gained unauthorized access to, and encrypted certain of, the company’s systems,” Inotiv says.
“The cybersecurity incident has caused, and is expected to continue to cause, disruptions to certain business operations of the company,” it continues.
According to Inotiv, the ransomware attack prevented it from accessing certain networks and systems, including parts of its internal data storage and internal business applications.
To reduce impact from the incident while working on restoring the affected systems, Inotiv transitioned some of its operations to offline alternatives.
“While the company is working diligently to restore affected functions and systems access, the timeline for a full restoration is not yet known,” Inotiv told the SEC.
While the pharmaceutical firm has not shared details on the threat actor responsible for the attack, the Qilin ransomware group claimed the incident on August 11, when it added Inotiv to its Tor-based leak site.
Qilin says it stole roughly 176 gigabytes of data from Inotiv, representing agreements, internal procedures, financial documents, purchase orders, and other business documents.
SecurityWeek has emailed Inotiv for a statement on the matter and will update this article if the company responds.
Based in Indiana, Inotiv is a contract research organization focused on new drugs and medical devices. It has roughly 2,000 employees.
Related: Gambling Tech Firm Bragg Discloses Cyberattack
Related: US Seizes $2.8 Million From Zeppelin Ransomware Operator
Related: Manpower Says Data Breach Stemming From Ransomware Attack Impacts 140,000
Related: Anticipating the Cyber Frontier: Top Predictions for 2025
